Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis

Kamishirado, Hirotoshi; Inoue, Teruo; Mizoguchi, Keiichi; Uchida, Toshihiko; Nakata, Takashi; Sakuma, Masashi; Takayanagi, Kunio; Morooka, Shigenori

doi:10.1067/mjh.2002.122874

Cited by 36 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The antiplatelet agent cilostazol has been mainly used for secondary prevention of cardiovascular events related to advanced atherosclerosis or for control of symptoms in the patients with intermittent claudication or skin ulcers [10][11][12]. However, the present study showed that cilostazol could attenuate the increase of carotid IMT in type 2 diabetics, and these results were consistent with recent reports about the preventive effect of cilostazol on early atherosclerosis in diabetics [13,14].…”

Section: Discussionsupporting

confidence: 79%

Effect of Cilostazol, a Phosphodiesterase Inhibitor, on Carotid IMT in Japanese Type 2 Diabetic Patients

et al. 2004

View full text Add to dashboard Cite

Abstract. The aim of this study was to investigate the effect of cilostazol, a cAMP phosphodiesterase inhibitor, on carotid artery intima-media thickness (IMT) and on the incidence of cardiovascular events in Japanese subjects with type 2 diabetes. A total of 62 type 2 diabetic subjects were allocated equally to the cilostazol treatment group (n = 31) and the control group (n = 31). Carotid IMT was evaluated before and after treatment using B-mode ultrasonography. After the study period (mean ± SD: 2.6 ± 0.17 years), carotid IMT showed a significantly greater increase in the control group than in the cilostazol group (0.12 ± 0.14 mm vs. 0.04 ± 0.02 mm, p<0.05). In the control group, 1 out of 31 patients suffered from symptomatic cerebral infarction and 1 had angina pectoris during the observation period. On the other hand, no subject in the cilostazol group developed cardiovascular events during the study period. At baseline, the diabetic patients given cilostazol had a significantly lower HbA 1c level than the control subjects, but the other atherosclerotic risk factors (BMI, blood pressure, and serum lipids) and the duration of diabetes did not differ between the two groups. These results indicate that cilostazol therapy can attenuate the increase of carotid artery IMT in Japanese subjects with type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 79%

Effect of Cilostazol, a Phosphodiesterase Inhibitor, on Carotid IMT in Japanese Type 2 Diabetic Patients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…4,5 Thus, the alternative regimen of "cilostazol + aspirin" has been proposed because of its potentially less severe ADR. Several previous studies have demonstrated that the new combination is a safe and effective post-stenting antithrombotic regimen that is comparable to the standard ticlopidine + aspirin regimen; 13,18,19 However, in the present study, the rate of SAT was significantly higher in patients given the cilostazol combination. In other words, it was inadequate as a post-stenting treatment regimen.…”

Section: Discussioncontrasting

confidence: 55%

Randomized Comparison of Cilostazol vs Ticlopidine for Antiplatelet Therapy After Coronary Stenting

Takeyasu

Watanabe

Noguchi

et al. 2005

Circ J

View full text Add to dashboard Cite

Background Cilostazol and ticlopidine are commonly prescribed for prevention of thrombosis after coronary stenting, but few studies have compared them. Methods and ResultsIn the present study 642 patients who underwent stenting were randomized to treatment either with cilostazol + aspirin (C group, 321 patients) or ticlopidine + aspirin (T group, 321 patients). Quantitative coronary angiography (QCA) was performed immediately after stenting and at the 6-month follow-up. Treatment was continued until follow-up angiography. Baseline patient characteristics did not differ significantly. With the exception of a higher rate of stenting in a venous graft in the C group, there were no differences in angiographic characteristics or stent type. Baseline QCA analysis of the reference diameter, minimal lumen diameter (MLD) showed no significant differences. Follow-up QCA analysis of the MLD showed no significant differences. There were also no differences in restenosis or target lesion revascularization rates, or in the incidence of adverse reactions. However, the rate of subacute thrombosis (SAT) was significantly higher in the C group than in the T group (2% vs 0.3%, p=0.02). Conclusion In the present study there was a similar restenosis rate with cilostazol or ticlopidine, but the rate of SAT was significantly higher with cilostazol. There was no significant difference in adverse reactions. (Circ J 2005; 69: 780 -785)

show abstract

“…[6][7][8][9][10][11][12] Cilostazol improves the walking distance in patients with intermittent claudication [13][14][15][16][17] and significantly reduces restenosis and TLR after successful percutaneous coronary intervention. [18][19][20][21][22][23][24][25] Nonetheless, the efficacy of cilostazol as an adjunctive therapy after PTA in the FPA is unclear, so we undertook to investigate this issue.…”

mentioning

confidence: 99%

Cilostazol Reduces Target Lesion Revascularization After Percutaneous Transluminal Angioplasty in the Femoropopliteal Artery

Iida

Nanto

Uematsu

et al. 2005

Circ J

View full text Add to dashboard Cite

Background Although percutaneous transluminal angioplasty (PTA) is being widely used for the treatment of stenosis of peripheral arteries, the high in-stent restenosis rate (50-60%) in the femoropopliteal artery still remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation. Methods and Results A total of 141 consecutive patients scheduled for PTA in the femoropopliteal artery between September 1999 and April 2004 were retrospectively analyzed for the use of cilostazol. Target lesion revascularization (TLR) was defined as repeated PTA in patients who had a recurrence of symptoms with diameter stenosis >50% by angiography. Patient and lesion characteristics were similar between the cilostazol (+) and cilostazol (-) groups. Use of other medications was similar between the groups, except for ticlopidine, which was more frequently used in the cilostazol (-) than in the cilostazol (+) group (15% vs 61%, p<0.01). TLR was significantly reduced in the cilostazol (+)

show abstract

Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis

Cited by 36 publications

References 0 publications

Effect of Cilostazol, a Phosphodiesterase Inhibitor, on Carotid IMT in Japanese Type 2 Diabetic Patients

Effect of Cilostazol, a Phosphodiesterase Inhibitor, on Carotid IMT in Japanese Type 2 Diabetic Patients

Randomized Comparison of Cilostazol vs Ticlopidine for Antiplatelet Therapy After Coronary Stenting

Cilostazol Reduces Target Lesion Revascularization After Percutaneous Transluminal Angioplasty in the Femoropopliteal Artery

Contact Info

Product

Resources

About